AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared...
AGOURA HILLS, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments...
Recently Published Findings Support Further Development in Anxiety-Related DisordersSOLANA BEACH, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL),...
Dr. Richard Caruso Dr. Richard Caruso, founder and former Chairman and CEO of Integra LifeSciencesPRINCETON, N.J., Aug. 16, 2022 (GLOBE...
LA JOLLA, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market...
AUSTIN, Texas, Aug. 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,...
Two-Year, In-Depth Analysis Suggests Ovia’s Platform Can Also Reduce Maternity Claims CostsBOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- A digital...
CHERRY HILL, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an...
Lead myotonic dystrophy type 1 (DM1) candidate continues to show promising preclinical data, including the pharmacokinetics (PK) and biodistribution data...
-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including...
-- PAS002 is a proprietary DNA tolerizing vaccine construct encoding GlialCAM ---- PAS002 effectively reduces disease severity, delays onset of...
• UB-612 Phase 3 COVID-19 Heterologous Boost Trial on Track for Topline Readout in Fourth Quarter of 2022 • UB-312...
WVE-006 announced as investigational development candidate for AATD with CTA submissions expected in 2023; first-in-class RNA editing candidate and most advanced...
PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing...
HONG KONG, Aug. 09, 2022 (GLOBE NEWSWIRE) -- WIMI Hologram Academy, working in partnership with the Holographic Science Innovation Center,...
Strengthened leadership team with appointment of Sergey Yurasov, M.D., Ph.D., as Chief Medical OfficerAdvanced MasterKey therapy pipeline with first patient...
Anticipates filing an Investigational New Drug application for OV329, a potent GABA-aminotransferase inhibitor, and initiating a Phase 1 trial in...
The trial's objectives are to evaluate the safety, tolerability and efficacy of SciSparc's SCI-210 in children and adolescents with ASD...
Glen Rock, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in...
Presented Additional Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Utility in...